NEW YORK--(BUSINESS WIRE)--Pfizer will present new data highlighting the company’s commitment to a personalized approach to oncology clinical research, which includes the use of targeted agents in specific patient populations in several advanced and difficult-to-treat cancers. These data will be presented later this month at the 45th Annual American Society of Clinical Oncology (ASCO) annual meeting in Orlando from May 29 to June 2.